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Summary
Objectives: The plasma brain natriuretic peptide concentrations (brain natriuretic
peptide (BNP) levels) have a prognostic value of mortality and morbidity in patients
with chronic heart failure and in a community-based population. However, the prog-
nostic value of BNP levels in outpatients of general practice is not well known. This
study investigated the relations of BNP levels to cardiovascular events and death in
general practice.
Methods: This study covered 3123 consecutive outpatients (mean age 59.3± 15.3
years; 42% men). BNP levels were measured by immunoradiometric assay (Shionogi)
in an occasional sample of each person.
Results: During a median follow-up of 5.5 years, 271 patients underwent a cardio-
vascular event (heart failure 65, coronary heart disease events 63, arrhythmia 26,
stroke 96, others 21), 92 died from cardiovascular disease and 227 died from all
causes. The patients were stratiﬁed into two groups based on a cut-off level of BNP
(100 pg/ml). A BNP level 100 pg/ml was associated with a hazard ratio (95% con-
ﬁdence interval) of 4.6 (3.5—6.1) for cardiovascular events compared with a BNP
<100 pg/ml (p < 0.0001), 7.0 (4.5—10.9) for cardiovascular mortality (p < 0.0001),
3.2 (2.4—4.2) for all-cause mortality (p < 0.0001), 18.8 (11.3—31.1) for heart failure
(p < 0.0001), 2.5 (1.5—3.9) for stroke (p = 0.0002), 5.0 (2.4—11.2) for atrial ﬁbrilla-
tion (p < 0.0001); however, it was 0.6 (0.2—1.7) for coronary heart disease events
(p = 0.337). Furthermore, the result of investigation with stratiﬁcation into six groups
based on BNP cut-off levels (20, 40, 100, 200, 500 pg/ml) showed that cardiovascu-
lar events, cardiovascular mortality, all-cause mortality, heart failure, stroke, and
atrial ﬁbrillation increased stepwise as BNP levels increased (p < 0.0001), except for
coronary heart disease events (p = 0.986).
∗ Corresponding author. Tel.: +81 258 39 8888; fax: +81 258 37 6822.
E-mail address: kalove@etude.ocn.ne.jp (K. Tsuchida).
0914-5087/$ — see front matter © 2008 Japanese College of Cardiology. Published by Elsevier Ireland Ltd. All rights reserved.
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Conclusions: In general practice, BNP levels predicted the risk of cardiovascular events
other than coronary heart disease events and of death.
e of Cardiology. Published by Elsevier Ireland Ltd. All rights
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ric assay method (IRMA) using a Shionoria BNP assay
kit (Shionogi, Osaka, Japan) for the one-point blood
sample taken in a sitting position.© 2008 Japanese Colleg
reserved.
ntroduction
rain natriuretic peptide (BNP) is secreted by
he heart, especially from the ventricles [1—3].
he plasma BNP concentrations (BNP levels) are
orrelated positively with the left ventricular
nd-diastolic pressure and negatively with the
eft ventricular ejection fraction [4—7], so BNP
evels should be measured to evaluate left ven-
ricular function. BNP levels have proved to be
ood markers of congestive heart failure. In addi-
ion, BNP levels are useful in screening test
or left ventricular dysfunction and also heart
isease.
Some studies [8—11] have shown that BNP levels
ave a prognostic value of mortality and mor-
idity in patients with chronic heart failure. In
he Valsartan Heart Failure Trial (Val-HeFT) study
n patients with heart failure, BNP in quartiles
<40, 41—96, 97—237, and 238 pg/ml) showed
igniﬁcant quartile-dependent increase in mortal-
ty and morbid events [8]. The Framingham study
or community-based populations showed that BNP
evels of 20 pg/ml (for men) and 23.3 pg/ml (for
omen) were useful thresholds for predicting car-
iovascular events [12]. However, the prognostic
alue of BNP levels in outpatients of general prac-
ice is unknown.
This study investigated the relations of BNP
evels to cardiovascular events and death in gen-
ral practice, by stratiﬁcation into six or two
roups based on routinely used cut-off levels
f BNP.
ubjects and methods
ubjects
his study included 3123 consecutive outpatients
n the Tsuchida Clinic of Internal Medicine and Car-
iology, 1307 men and 1816 women (20—98 years
ith an average age of 59.3± 15.3 years), whose
NP levels were measured to evaluate left ven-
ricular function from 1999 to 2002. The patients
ere treated according to the relevant guide-
ines and followed up until 31 December 2006.
he median follow-up period was 5.5 years (max:
4
i
b.5 years). Diagnosis was based on history, physi-
al examination, laboratory ﬁndings, chest X-rays,
lectrocardiograms, and partly echocardiograms
36.2%).
The patient backgrounds are summarized in
able 1. Non-cardiovascular diseases could be
emonstrated in 2149 (69%), whereas cardiovascu-
ar diseases were found in 974 (31%): congestive
eart failure in 89; hypertrophic cardiomyopathy
n 67; dilated cardiomyopathy in 15; old myocar-
ial infarction in 67; effort angina in 55; vasospastic
ngina in 130; valvular disease in 116; chronic atrial
brillation in 140; paroxysmal atrial ﬁbrillation
n 231; paroxysmal supraventricular tachycardia
n 116; ventricular tachycardia in 11; pacemaker
mplantation in 29; congenital heart disease in
7; hypertension in 1550 (hypertension with car-
iovascular disease in 622 including 226 with
ypertensive heart disease; hypertension without
ardiovascular disease in 928); cerebrovascular
isease in 89; diabetes mellitus in 340; hyper-
ipidemia in 1045; hypertension + diabetes melli-
us in 238; hypertension + hyperlipidemia in 640;
iabetes mellitus + hyperlipidemia in 151, hyper-
ension + diabetes mellitus + hyperlipidemia in 107;
hronic obstructive pulmonary disease in 104;
astric and duodenal ulcer in 128; including
ome patients with more than one disease. As
egards hypertension, we classiﬁed hypertension
nto ‘‘non-cardiovascular disease,’’ except for
‘with cardiovascular disease’’ or ‘‘hypertensive
eart disease (that is, with the ﬁndings of left ven-
ricular hypertrophy in the electrocardiogram).’’
he study protocol was approved by the Ethics Com-
ittee of Tsuchida Clinic of Internal Medicine and
ardiology.
ethods
NP levels were measured by the immunoradiomet-We selected useful cut-off levels of BNP (20,
0, 100, 200, 500 pg/ml), drawing on many stud-
es [8—27]. Patients were stratiﬁed into six groups
ased on these cut-off levels of BNP (<20, 20—40,
214 K. Tsuchida, K. Tanabe
Table 1 Characteristics of the study population
Number of patients 3123
Age, years (mean± S.D.) 59.3± 15.3
Sex
Male 1307 (42%)
Female 1816 (58%)
Underlying diseasea
Cardiovascular disease 974 (31%)
Non-cardiovascular disease 2149 (69%)
Congestive heart failure 89 (2.8%)
Hypertrophic cardiomyopathy 67 (2.1%)
Dilated cardiomyopathy 15 (0.5%)
Coronary heart disease 252 (8.1%)
Old myocardial infarction 67 (2.1%)
Angina pectoris 55 (1.8%)
Vasospastic effort 130 (4.2%)
Valvular disease 116 (3.7%)
Chronic atrial ﬁbrillation 140 (4.5%)
Paroxysmal atrial ﬁbrillation 231 (7.4%)
Paroxysmal supraventricular tachycardia 116 (3.7%)
Ventricular tachycardia 11 (0.4%)
Pacemaker implantation, post-op. 29 (0.9%)
Congenital heart disease 17 (0.5%)
Cerebrovascular disease 89 (2.8%)
Hypertension (HT) 1550 (49.6%)
Hypertension with cardiovascular disease
(including hypertensive heart disease: 226)
622 (19.9%)
Hypertension without cardiovascular disease 928 (29.7%)
Diabetes mellitus (DM) 340 (10.9%)
Hyperlipidemia (HL) 1045 (33.5%)
HT +DM 238 (7.6%)
HT +HL 640 (20.5%)
DM+HL 151 (4.8%)
HT +DM+HL 107 (3.4%)
Chronic obstructive pulmonary disease 104 (3.3%)
Gastric and duodenal ulcer 128 (4.1%)
Echocardiography 1132 (36.2%)
Medication
Calcium-channel blockers 1211 (38.8%)
ACEI/ARB 364 (11.6%)
Beta blockers 141 (4.5%)
Digitalis 419 (13.4%)
Thiazide 137 (4.4%)
Antialdosterone agents 103 (3.3%)
Nitrates 99 (3.2%)
Statins 807 (25.8%)
Warfarin 127 (4.1%)
Antiplatelet drugs 430 (13.8%)
sin II
iACEI, angiotensin converting enzyme inhibitors; ARB, angioten
a Some patients with more than one disease.
40—100, 100—200, 200—500,500 pg/ml). Further-
more, some studies of patients with heart failure
[10,23] showed that BNP levels more than about
100 pg/ml were signiﬁcantly related to mortality
andmorbidity, so the patients were otherwise strat-
(
d
Creceptor blockers.
ﬁed into two groups based on cut-off levels of BNP
<100 and 100 pg/ml).
The primary endpoint was a composite of car-
iovascular events (hospitalization and death).
omponents of the endpoints included the follow-
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ng: heart failure, coronary heart disease events
acute myocardial infarction, unstable angina),
troke (infarction, hemorrhage), arrhythmia, dis-
ecting aneurysm, peripheral arterial disease,
nfective endocarditis, acute myocarditis, renal
nfarction, pulmonary infarction, embolism of the
uperior mesenteric artery, and sudden cardiac
eath. The ﬁrst of these events was noted as the
rimary event. Any component of a composite pri-
ary endpoint for which a patient could be counted
nce in each category was treated as a second end-
oint. Death from any cause was also designated
secondary endpoint. Furthermore, patients were
ollowed for the development of chronic atrial ﬁb-
illation.
tatistical analysis
alues are shown as mean± standard deviation.
ime-to-event curves for the endpoints were esti-
ated by the Kaplan—Meier method for the
ntire follow-up period. The log-rank test was
sed to examine the association of BNP levels.
azard ratio (HR) and 95% conﬁdence interval
CI) were calculated and adjusted for age, sex,
he presence or absence of hypertension, dia-
etes mellitus, and hyperlipidemia with the Cox’s
roportional hazards model. All analyses were
erformed with the use of StatView (version
.0). Signiﬁcance levels were p < 0.05 in these
nalyses.
esults
aplan—Meier curves for the endpoints
aplan—Meier analyses were performed on the
umulative event-free rates in patients stratiﬁed
nto six groups based on cut-off levels (20, 40,
00, 200, 500 pg/ml) (Fig. 1). Using the six-group
lassiﬁcation, the number of patients with a BNP
20 pg/ml was 1950/3123 (62%); with a BNP of
0—40 pg/ml 600 (19%); of 40—100 pg/ml 377 (12%);
f 100—200 pg/ml 122 (4%); of 200—500 pg/ml 59
2%); of500 pg/ml 15 (0.5%). Otherwise they were
tratiﬁed into two groups based on cut-off level
100 pg/ml). The number with a BNP <100 pg/ml in
he two-group classiﬁcation was 2927/3123 (94%),
nd with a BNP 100 pg/ml, 196 (6%).
The number of cardiovascular events was
71/3123 (9%): heart failure 65, coronary heart dis-
ase events 63 (acute myocardial infarction 31,
nstable angina 32), arrhythmia 24 (sick sinus
t
1
s
i
s215
yndrome 7, atrioventricular block 3, ventricu-
ar tachycardia 2, supraventricular tachycardia
, others 6), stroke 96 (infarction 83, intracra-
ial hemorrhage 6, subarachnoidal hemorrhage
), dissecting aneurysm 5, peripheral arterial dis-
ase 6, infective endocarditis 3, acute myocarditis
, renal infarction 1, pulmonary infarction 1,
nd cardiac sudden death 4. The patients were
tratiﬁed into six groups based on cut-off levels
20, 40, 100, 200, 500 pg/ml), and a cumulative
ardiovascular event-free curve was constructed
ccording to Kaplan—Meier analysis. Based on
aplan—Meier analysis of a six-group stratiﬁcation,
t was found that as BNP levels increased, the cumu-
ative cardiovascular event-free rate decreased
igniﬁcantly (p < 0.0001). Furthermore, patients
ere stratiﬁed into two groups based on cut-
ff level of BNP (100 pg/ml), and a cumulative
ardiovascular event-free curve was constructed
ccording to Kaplan—Meier analysis. Cumulative
ardiovascular event-free rate, as evaluated by
aplan—Meier analysis, was signiﬁcantly lower with
NP 100 pg/ml (p < 0.0001).
The number of deaths from cardiovascular
isease was 92/3123 (3%): heart failure 35, arrhyth-
ia 3, coronary heart disease events 6 (acute
yocardial infarction 6), stroke 35 (infarction 31,
ntracranial hemorrhage 1, subarachnoidal hemor-
hage 3), dissecting aneurysm 5, peripheral artery
isease 1, pulmonary infarction 1, embolism of
he superior mesenteric artery 2, and cardiac sud-
en death 4. Based on Kaplan—Meier analysis of
he 6-groups stratiﬁcation, it was found that, as
NP levels increased, the cumulative survival rate
ecreased signiﬁcantly (p < 0.0001). Furthermore,
atients were stratiﬁed into two groups based
n cut-off level of BNP (100 pg/ml), and cumula-
ive survival curve was constructed according to
aplan—Meier analysis. Cumulative survival rate,
s evaluated by Kaplan—Meier analysis, was signif-
cantly lower with BNP 100 (p < 0.0001).
The number of deaths from all causes were
27/3123 (7%): from cardiovascular disease, 92 (as
as stated above); malignant tumors, 70 (lung
8, stomach 12, colon 13, pancreas 4, esopha-
us 2, liver 2, gallbladder 2, malignant lymphoma
, others 13); pneumonia and chronic obstructive
ulmonary disease, 16; pulmonary tuberculosis 1,
ronchial asthma 1, renal failure 5, ileus 4, liver
irrhosis 2, gastro-intestinal bleeding 3, Parkin-
on syndrome 2, senile dementia 1, senility 2,
rafﬁc accident 1, suicide 5, and unknown causes
8. Based on a Kaplan—Meier analysis of 6-group
tratiﬁcation, it was found that, as BNP levels
ncreased, the cumulative survival rate decreased
igniﬁcantly (p < 0.0001). Patients were also strat-
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Figure 1 Kaplan—Meier curves for cardiovascular events, cardiovascular mortality and all-cause mortality. Patients
were stratiﬁed into six groups based on cut-off levels of brain natriuretic peptide (BNP) (20, 40, 100 200, 500 pg/ml),
and were otherwise stratiﬁed into two groups based on cut-off levels of BNP (100 pg/ml). The cumulative cardiovascular
as B
I
F
a
y
d
a
r

3
6event-free rate and survival rate decreased signiﬁcantly,
iﬁed into two groups based on a cut-off level of
BNP (100 pg/ml), and a cumulative survival curve
was constructed according to Kaplan—Meier analy-
sis. The cumulative survival rate, as evaluated by
Kaplan—Meier analysis, was signiﬁcantly lower with
a BNP 100 pg/ml (p < 0.0001).
In other secondary analyses (Fig. 2), as evalu-
ated by Kaplan—Meier analysis for heart failure,
stroke, and atrial ﬁbrillation, it was found that,
as BNP levels increased, the cumulative cardio-
vascular event-free rate decreased signiﬁcantly
(p < 0.0001). But only with regard to coronary heart
disease events, the cumulative event-free rate
was not signiﬁcantly associated with the BNP level
(p = 0.1144).
(
t
f
(NP levels increased (p < 0.0001).
ncidence of death or cardiovascular events
ig. 3 shows the incidence of cardiovascular events
nd death during a median follow-up of 5.5
ears. The incidence of cardiovascular events,
eath from cardiovascular disease, death from
ny cause, heart failure, stroke, and atrial ﬁb-
illation were signiﬁcantly higher with a BNP
100 pg/ml than a BNP < 100 pg/ml: HR 4.63 (95%CI
.52—6.08) for cardiovascular events (p < 0.0001),
.99 (4.49—10.88) for cardiovascular mortality
p < 0.0001), 3.15 (2.35—4.21) for all-cause mor-
ality (p < 0.0001), 18.77 (11.33—31.08) for heart
ailure (p < 0.0001), 2.45 (1.54—3.89) for stroke
p = 0.0002), and 4.96 (2.41—11.22) for atrial ﬁb-
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Figure 2 Kaplan—Meier curves for heart failure, coronary heart disease events, stroke and atrial ﬁbrillation. Patients
were stratiﬁed into six groups based on cut-off levels of brain natriuretic peptide (BNP) (20, 40, 100, 200, 500 pg/ml),
and were otherwise stratiﬁed into two groups based on cut-off levels of BNP (100 pg/ml). As brain natriuretic peptide
(BNP) levels increased, the cumulative cardiovascular event-free rate for heart failure, stroke and atrial ﬁbrillation
decreased signiﬁcantly (p < 0.0001), but only with regard to coronary heart disease events, it was not signiﬁcantly
associated with the BNP level (p = 0.1144).
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Figure 3 The incidence of cardiovascular events, cardiovascular mortality, all-cause mortality, heart failure, stroke
and atrial ﬁbrillation were signiﬁcantly higher with a brain natriuretic peptide (BNP)100 pg/ml than a BNP <100 pg/ml
(p < 0.0001). However the incidence of coronary heart disease events was not signiﬁcantly associated with BNP levels
(p = 0.3367). Hazard ratios are adjusted for sex (male), age, hypertension, diabetes and hyperlipidemia.
Figure 4 (A) Using six-group classiﬁcation based on cut-off levels of brain natriuretic peptide (BNP) (20, 40, 100,
200, 500 pg/ml), the hazard ratio (HR) (versus BNP <20 pg/ml) for cardiovascular events increased stepwise as the
BNP levels increased, signiﬁcantly (p < 0.0001), by univariate analysis. (B) The incidence of cardiovascular events was
signiﬁcantly higher with BNP 100 pg/ml than with BNP <100 pg/ml, not only in the patients with cardiovascular
diseases (p < 0.0001), but also with non-cardiovascular diseases (p = 0.0134). The incidence of all-cause mortality was
also signiﬁcantly higher with BNP 100 pg/ml than with BNP <100 pg/ml, not only in the patients with cardiovascular
diseases (p < 0.0001), but also with non-cardiovascular diseases (p = 0.0004), by univariate analysis.
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illation (p < 0.0001). However the incidence of
oronary heart disease events was not signiﬁ-
antly associated with BNP levels (HR 0.60, 95%CI
.22—1.69, p = 0.3367).
Furthermore, as a result of investigation with
tratiﬁcation into six groups based on cut-off
evels of BNP (20, 40, 100, 200, 500 pg/ml), it
as seen that cardiovascular events, cardiovas-
ular mortality, all-cause mortality, heart failure,
troke, and atrial ﬁbrillation increased stepwise
s the BNP levels increased (p < 0.0001), except
o

t
igure 5 Multivariate analysis for endpoints (cardiovascula
sing Cox’s proportional hazards model. The incidence of card
atriuretic peptide (BNP) 100 pg/ml, age, gender (men), h
ith BNP 100 pg/ml, age and diabetes; and coronary heart
yperlipidemia.219
n the case of coronary heart disease events
p = 0.986).
Fig. 4(A) shows that the HR (95%CI) (versus a BNP
20 pg/ml) for cardiovascular events increased sig-
iﬁcantly: a BNP of 20—40 pg/ml 1.86 (1.29—2.67);
BNP of 40—100 pg/ml 3.65 (2.59—5.15); a BNP
f 100—200 pg/ml 12.04 (8.40—17.25); a BNP
f 200—500 pg/ml 13.84 (9.00—21.29); a BNP
500 pg/ml 27.31 (14.82—50.31).
In patients with cardiovascular diseases,
he incidence of cardiovascular events was
r events, heart failure, coronary heart disease events)
iovascular events was signiﬁcantly associated with brain
ypertension and diabetes; heart failure was associated
disease events, with age, gender (men), diabetes and
a
h
a
C
a
s
a

t
a
a
d
D
T
n220
signiﬁcantly higher with BNP 100 pg/ml
than with BNP <100 pg/ml (HR of 4.45, 95%CI
3.36—5.89; p < 0.0001). Also in patients with
non-cardiovascular diseases, the incidence of
cardiovascular events was signiﬁcantly higher with
BNP 100 pg/ml than a BNP < 100 pg/ml (HR 5.90,
95%CI 1.45—24.10; p = 0.0134). The incidence of
all-cause mortality was also signiﬁcantly higher
with BNP 100 pg/ml than with BNP < 100 pg/ml,
not only in patients with cardiovascular diseases
(HR 4.98, 95%CI 3.63—6.84; p < 0.0001), but also
in patients with non-cardiovascular diseases (HR
8.02, 95%CI 2.50—25.48; p = 0.0004), as shown in
Fig. 4(B).
Factors affecting prognosis of
cardiovascular diseasesWe assessed the effects of BNP 100 pg/ml, age,
gender (men), hypertension, diabetes mellitus, and
hyperlipidemia on the endpoints using Cox’s propor-
tional hazards model (Figs. 5 and 6). The incidence
of cardiovascular events was signiﬁcantly associ-
i
t
l
c
l
Figure 6 Multivariate analysis for endpoints (stroke, atrial ﬁb
was signiﬁcantly associated with brain natriuretic peptide (B
lation was associated with BNP 100 pg/ml and age.K. Tsuchida, K. Tanabe
ted with BNP 100 pg/ml, age, gender (men),
ypertension, and diabetes, and heart failure was
ssociated with BNP 100 pg/ml, age, and diabetes.
oronary heart disease events were associated with
ge, gender (men), diabetes, and hyperlipidemia;
troke was associated with BNP 100 pg/ml, age,
nd hypertension; and atrial ﬁbrillation, with BNP
100 pg/ml and age. Finally, cardiovascular mor-
ality was associated with BNP 100 pg/ml, age,
nd diabetes, and all-cause mortality was associ-
ted with BNP 100 pg/ml, age, gender (men), and
iabetes.
iscussion
his study shows that BNP is an important prog-
ostic marker of cardiovascular events and death
n outpatients of general practice. The stratiﬁca-
ion into six groups based on routinely used cut-off
evels of BNP demonstrated that the incidence of
ardiovascular events increased stepwise as BNP
evels increased [8]. In addition, BNP levels had
rillation) using Cox’s proportional hazards model. Stroke
NP) 100 pg/ml, age and hypertension, and atrial ﬁbril-
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prognostic value of cardiovascular events and
ll-cause mortality not only in patients with under-
ying cardiovascular diseases, but also in those
ithout them, by stratiﬁcation into two groups
ased on the cut-off level (100 pg/ml). The Fram-
ngham study of a community-based sample of
346 persons without heart failure showed that
NP levels above the 80th percentile (20 pg/ml
or men and 23.3 pg/ml for women) were use-
ul as a threshold for predicting cardiovascular
vents [12]. In this study, we selected useful cut-
ff levels of BNP (20, 40, 100, 200, 500 pg/ml) that
ere seen in many studies. The ﬁndings of this
tudy was that these BNP cut-off levels had value
n the prognosis of cardiovascular events which
econﬁrmed that these cut-off levels were use-
ul for diagnosis and screening of cardiovascular
iseases.
As regards secondary endpoints, the incidence
f cardiovascular death, all-cause death, heart
ailure, stroke, and atrial ﬁbrillation were sig-
iﬁcantly higher with BNP 100 pg/ml than with
NP < 100 pg/ml. A few studies in community-based
amples showed that BNP levels had prognostic
alue regarding all-cause mortality. The present
tudy in outpatients of general practice demon-
trated that death from cardiovascular disease
nd death from any cause increased as BNP levels
ncreased.
Many studies in patients with heart failure
howed that BNP levels had a prognostic value for
ortality and morbidity. In the Val-HeFT study [8]
n 4284 patients with heart failure, BNP in quartiles
<40, 41—96, 97—237,238 pg/ml) showed a signif-
cant quartile-dependent increase in mortality and
orbid events. In this study, also in outpatients of
eneral practice, the stratiﬁcation based on cut-
ff levels of BNP (<20, 20—40, 40—100, 100—200,
00—500, 500 pg/ml) demonstrated that the inci-
ence of heart failure increased stepwise as BNP
evels increased.
In patients with coronary heart disease, BNP lev-
ls were deﬁnitely associated with acute phase and
utcome of myocardial infarction [13,21,22,26,27].
owever, in this study, we did not ﬁnd an
ssociation between BNP levels and the risk
f coronary heart disease events in outpatients
f general practice, reﬂecting a similar ﬁnd-
ng in the report of the Framingham study in
community-based population [12]. Further, this
tudy showed that the incidence of coronary heart
isease events was not associated with BNP lev-
ls but with age, gender (men), diabetes, and
yperlipidemia.
In this study, BNP levels were associated with
he risk of stroke in outpatients of general prac-
A
W
i221
ice, again reﬂecting the ﬁnding of the Framingham
tudy in a community-based population [12]. Fur-
hermore, we found that the incidence of stroke
as signiﬁcantly associated not only with BNP lev-
ls (p = 0.0002), but also with age (p < 0.0001) and
ypertension (p < 0.0131).
As to atrial ﬁbrillation, in this study, BNP levels
ere also associated with the risk of atrial ﬁbril-
ation in patients seen in general practice, as the
eport of the Framingham study also stated [12].
ur previous study in outpatients with paroxysmal
trial ﬁbrillation [28] showed that BNP levels during
trial ﬁbrillation attack (median: 102 pg/ml) was
ncreased by 66 (median) pg/ml (2.4-fold) com-
ared with BNP levels during sinus rhythm (median:
9 pg/ml). In addition, the substantial and signiﬁ-
ant BNP elevation in asymptomatic cases (median
NP during sinus rhythm: 31 pg/ml, during atrial
brillation attack: 71 pg/ml) may indicate that BNP
levation of unknown origin may be attributed to
he occurrence of asymptomatic atrial ﬁbrillation
ttack.
tudy limitations
he present study has some limitations. First, we
ould not determine the cause of death of 18 sub-
ects (8.1% of 223 deaths in all) in this study. This
ay be inevitable in an observation study of out-
atients of general practice. Second, the study
opulation consisted of 3123 outpatients of one
ocal clinic in Japan, who were treated according
o the accepted guidelines and by BNP-guided ther-
py [29,30]. Therefore, it was unavoidable that this
tudy showed a certain amount of bias in relation
o patient background, diagnosis, and treatment.
onclusion
n general practice, plasma BNP concentrations
redicted the risk of cardiovascular events, car-
iovascular mortality, all-cause mortality, heart
ailure, stroke, and atrial ﬁbrillation, except for
oronary heart disease events. In addition, BNP
evels had a prognostic value of cardiovascular
vents and all-cause mortality not only in patients
ith underlying cardiovascular diseases, but also in
hose without them.cknowledgments
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